BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25786552)

  • 1. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA.
    Aliyev A; Gupta M; Nasr C; Hatipoglu B; Milas M; Siperstein A; Berber E
    Endocr Pract; 2015 Jul; 21(7):777-81. PubMed ID: 25786552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas.
    Novosel T; Ritter HE; Gupta M; Harvey A; Mitchell J; Berber E; Siperstein A; Milas M
    Surgery; 2009 Dec; 146(6):1081-9. PubMed ID: 19958935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
    Chia SY; Milas M; Reddy SK; Siperstein A; Skugor M; Brainard J; Gupta MK
    J Clin Endocrinol Metab; 2007 Feb; 92(2):468-75. PubMed ID: 17118994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer.
    Milas M; Barbosa GF; Mitchell J; Berber E; Siperstein A; Gupta M
    Ann Surg Oncol; 2009 Feb; 16(2):473-80. PubMed ID: 19015922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of thyroid-stimulating hormone receptor mRNA with real-time PCR for early diagnosis of papillary thyroid microcarcinoma.
    Qiu J; Zhang Y; Guo X; Zeng F; Zhao C; Qiu X; Wu X
    Neoplasma; 2010; 57(4):360-4. PubMed ID: 20429628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer.
    Aliyev A; Soundararajan S; Bucak E; Gupta M; Hatipoglu B; Nasr C; Siperstein A; Berber E
    Surgery; 2015 Oct; 158(4):1089-93; discussion 1093-4. PubMed ID: 26212344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.
    So YK; Son YI; Baek CH; Jeong HS; Chung MK; Ko YH
    Ann Surg Oncol; 2012 Mar; 19(3):990-5. PubMed ID: 21879263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between preoperative thyrotrophin and clinicopathological and aggressive features of papillary thyroid cancer.
    Tam AA; Ozdemir D; Aydın C; Bestepe N; Ulusoy S; Sungu N; Ersoy R; Cakir B
    Endocrine; 2018 Mar; 59(3):565-572. PubMed ID: 29374347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
    Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
    Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.
    Zhang Y; Pan J; Xu D; Yang Z; Sun J; Sun L; Wu Y; Qiao H
    Oncol Rep; 2018 Dec; 40(6):3611-3624. PubMed ID: 30542708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection.
    Chung YS; Kim JY; Bae JS; Song BJ; Kim JS; Jeon HM; Jeong SS; Kim EK; Park WC
    Thyroid; 2009 Mar; 19(3):241-6. PubMed ID: 19265495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma.
    Yuan J; Li J; Chen X; Lin X; Du J; Zhao G; Chen Z; Wu Z
    Bull Cancer; 2017 Jun; 104(6):516-523. PubMed ID: 28476312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma.
    Gao Y; Qu N; Zhang L; Chen JY; Ji QH
    Tumour Biol; 2016 Jun; 37(6):7453-9. PubMed ID: 26678888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma?
    Chang YW; Kim HS; Kim HY; Lee JB; Bae JW; Son GS
    Asian J Surg; 2016 Oct; 39(4):197-201. PubMed ID: 25913730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which papillary thyroid microcarcinoma should be treated as "true cancer" and which as "precancer"?
    Kaliszewski K; Diakowska D; Wojtczak B; Forkasiewicz Z; Pupka D; Nowak Ł; Rudnicki J
    World J Surg Oncol; 2019 May; 17(1):91. PubMed ID: 31146753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating epithelial cells as potential biomarkers for detection of recurrence in patients of papillary thyroid carcinoma with positive serum anti-thyroglobulin antibody.
    Li YR; Tseng CP; Hsu HL; Lin HC; Chen YA; Chen ST; Liou MJ; Lin JD
    Clin Chim Acta; 2018 Feb; 477():74-80. PubMed ID: 29229463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer.
    Chinnappa P; Taguba L; Arciaga R; Faiman C; Siperstein A; Mehta AE; Reddy SK; Nasr C; Gupta MK
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3705-9. PubMed ID: 15292293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial thyroidectomy for papillary thyroid microcarcinoma: Is completion total thyroidectomy indicated?
    Dobrinja C; Pastoricchio M; Troian M; Da Canal F; Bernardi S; Fabris B; de Manzini N
    Int J Surg; 2017 May; 41 Suppl 1():S34-S39. PubMed ID: 28506411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma.
    Park JP; Roh JL; Lee JH; Baek JH; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Am J Surg; 2014 Sep; 208(3):412-8. PubMed ID: 24602323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.